Quick Comparison
| SLU-PP-332 | Vitamin B12 | |
|---|---|---|
| Half-Life | Estimated several hours (limited pharmacokinetic data) | Hepatic stores last years; circulating methylcobalamin: 144 hours (6 days) |
| Typical Dosage | Preclinical only: mouse studies used 25-50 mg/kg oral. No established human dosing protocol. Very early stage compound with no human trials conducted. | Deficiency treatment: 1000 mcg intramuscular once weekly for 4-8 weeks, then 1000 mcg intramuscular once monthly for maintenance. Oral: 500-2000 mcg once daily. Sublingual: 1000-5000 mcg once daily. Pernicious anemia requires lifelong intramuscular injections. |
| Administration | Oral or injection (preclinical only) | Intramuscular injection, subcutaneous injection, oral, or sublingual |
| Research Papers | 1 papers | 30 papers |
| Categories |
Mechanism of Action
SLU-PP-332
SLU-PP-332 is a small molecule agonist of estrogen-related receptor alpha (ERRα), one of three orphan nuclear receptors in the ERR family. Despite its name, ERRα does not bind estrogen — it was named for its structural similarity to estrogen receptors. ERRα is constitutively active and functions as a master transcription factor for genes controlling mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation, particularly in metabolically active tissues like skeletal muscle, heart, and brown adipose tissue.
SLU-PP-332 enhances ERRα transcriptional activity by stabilizing its active conformation and promoting coactivator recruitment (particularly PGC-1α, which is both an ERRα target gene and an ERRα coactivator, creating a positive feed-forward loop). Activated ERRα binds to ERR response elements (ERREs) in the promoter regions of hundreds of metabolic genes, upregulating the entire oxidative metabolism gene program: mitochondrial electron transport chain subunits, fatty acid oxidation enzymes, TCA cycle enzymes, and mitochondrial transcription and replication factors.
The most striking effect in preclinical studies is the transformation of skeletal muscle fiber type composition. SLU-PP-332 treatment increases the proportion of slow-twitch (type I) and oxidative fast-twitch (type IIA) fibers while decreasing glycolytic fast-twitch (type IIB/IIX) fibers. Type I fibers are rich in mitochondria, capillaries, and myoglobin — they are the fibers that endurance athletes develop through years of training. By pharmacologically shifting this fiber type ratio, SLU-PP-332 produces endurance capacity gains similar to what would require months of aerobic training. In mouse studies published in 2023, treated animals ran significantly longer and farther on treadmill tests. This ERRα-mediated mechanism is distinct from and potentially complementary to AMPK-based exercise mimetics like AICAR, as it targets a different node in the mitochondrial biogenesis regulatory network.
Vitamin B12
Vitamin B12 (cobalamin) is a large organometallic molecule with a cobalt ion at its center, coordinated within a corrin ring. It is the most structurally complex vitamin and the only one containing a metal ion. Humans cannot synthesize B12 — it is produced exclusively by certain bacteria and archaea, and enters the human diet through animal products or bacterial fermentation. Absorption requires intrinsic factor (produced by gastric parietal cells), which binds B12 in the ileum for receptor-mediated endocytosis via the cubam receptor complex.
B12 functions as a cofactor for two essential enzymes. Methionine synthase (MS) uses methylcobalamin (methylB12) to catalyze the transfer of a methyl group from methyltetrahydrofolate (methyl-THF) to homocysteine, producing methionine and regenerating tetrahydrofolate (THF). This reaction sits at the intersection of two critical pathways: methionine is converted to S-adenosylmethionine (SAM), the universal methyl donor for DNA methylation, histone modification, neurotransmitter synthesis, and hundreds of other methylation reactions; and THF regeneration is essential for folate cycling and de novo nucleotide synthesis (required for DNA replication). B12 deficiency traps folate as methyl-THF ('methyl trap'), blocking DNA synthesis and causing megaloblastic anemia — red blood cell precursors cannot replicate their DNA properly, producing abnormally large, non-functional cells.
Methylmalonyl-CoA mutase uses adenosylcobalamin (adenosylB12) in mitochondria to convert methylmalonyl-CoA to succinyl-CoA, a key step in the catabolism of odd-chain fatty acids, branched-chain amino acids, and cholesterol. Deficiency causes methylmalonic acid accumulation, which is toxic to neurons and contributes to the peripheral neuropathy, subacute combined degeneration of the spinal cord, and cognitive decline seen in B12 deficiency. The neurological damage occurs because myelin synthesis requires both SAM-dependent methylation reactions (for phospholipid synthesis) and proper fatty acid metabolism (for myelin lipid composition), both of which depend on B12. Neurological damage from severe B12 deficiency can become irreversible if not treated promptly, which is why injectable B12 (which bypasses absorption barriers) is preferred for deficiency treatment.
Risks & Safety
SLU-PP-332
Serious
no human safety data exists, potential off-target effects on estrogen-responsive tissues and metabolic pathways are entirely unstudied.
Vitamin B12
Common
injection site pain, brief diarrhea.
Rare
acne, allergic reactions to cyanocobalamin formulation, itching, blood clots.
Full Profiles
SLU-PP-332 →
A compound developed at Washington University that activates estrogen-related receptor alpha. A next-generation exercise mimetic that enhances endurance and promotes slow-twitch muscle fiber transformation through a different mechanism than AICAR. Activates the same gene programs that endurance training induces, including mitochondrial growth and fat-burning metabolism.
Vitamin B12 →
An essential vitamin required for DNA synthesis, nerve function (myelin maintenance), and red blood cell formation. Deficiency is common, particularly in vegans, the elderly, those on metformin or proton pump inhibitors, and individuals with pernicious anemia. Injectable forms bypass the complex gut absorption pathway, making them the treatment of choice for severe deficiency and malabsorption.